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ABSTR ACT: Human Immunodeficiency Virus (HIV) is a retrovirus that can result in rare opportunistic infections occurring in humans. The onset of 
these infections is known as Acquired Immune Deficiency Syndrome (AIDS). Sexual transmission is responsible for the majority of infections 1, result-
ing in transmission of HIV due to infected semen or vaginal and cervical secretions containing infected lymphocytes. HIV microbicides are formulations 
of chemical or biological agents that can be applied to the vagina or rectum with the intention of reducing the acquisition of HIV. Tenofovir is an NRTI 
that is phosphorylated by adenylate kinase to tenofovir diphosphate, which in turn competes with deoxyadeosine 5’-triphosphate for incorporation into 
newly synthesized HIV DNA. Once incorporated, tenofovir diphosphate results in chain termination, thus inhibiting viral replication. Tenofovir has been 
formulated into a range of vaginal formulations, such as rings, tablets gels and films. It has been shown to safe and effective in numerous animal models, 
while demonstrating safety and acceptability in numerous human trials. The most encouraging results came from the CAPRISA 004 clinical trial which 
demonstrated that a 1% Tenofovir vaginal gel reduced HIV infection by approximately 39%.
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Introduction
HIV and AIDS. Human immunodeficiency virus (HIV) 
is a retrovirus that can result in rare opportunistic infections 
occurring in humans. The onset of these infections is known 
as acquired immunodeficiency syndrome (AIDS). HIV is 
subdivided into HIV-1 and HIV-2. HIV-2 is largely confined 
to West African countries, and is extremely rare in Europe, 
Central or East Africa and North America. While HIV-2 is 
similar to HIV-1, it has a different sequence of nucleotides 
in its genome. The major modes of HIV transmission are 
sexual contact, exposure to infected blood, infected needles 
and mother-to-child. Sexual transmission is responsible for 
the majority of infections;1 HIV is transmitted via infected 
semen or vaginal and cervical secretions containing infected 
lymphocytes.2
HIV destroys the human immune system by attacking 
the CD4+ T helper cells, a subgroup of lymphocytes, which 
are a type of white blood cell that is part of the adaptive 
immune system.3,4 This leaves the body susceptible to oppor-
tunistic infections, which leads to the onset of AIDS. HIV 
consists of a genome containing two identical single strands of 
RNA along with two molecules of reverse transcriptase that 
copies RNA into DNA. Two proteins, known as p7 and p9 are 
also associated with the genome, which is then surrounded 
by p17 proteins on the outer core and p24 on the inner core. 
Surrounding these core proteins is an envelope that contains 
two HIV-specific glycoproteins, gp41 and gp120 (see Fig. 1).5
All retroviruses have three common genes, gag, pol and env, 
which code for the main polyproteins of the virus. These poly-
proteins, when cleaved by viral protease, result in the  production 
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Figure 1. structure of hiV.
of the core proteins (p7, p9, p17 and p24), the replication enzymes 
(reverse transcriptase, protease and intergrase) and finally the 
envelope proteins (gp41 and gp120).6 HIV contains six unique 
genes that code for proteins required to regulate the expression of 
the HIV genome. Two of these genes are tat and rev, which code 
for a trans-activator protein and a regulator of mRNA transcrip-
tion, respectively. The tat protein binds to an RNA sequence on 
the genome known as TAR (trans-activation response element), 
which results in an increase in the number of RNA transcripts 
formed.7 The HIV genome also includes vif, upr, nef and upu 
genes, which help in the regulation of transcription.
HIV replication. The HIV replication cycle begins with 
attachment of the virus to CD4 receptors on certain cells of 
the immune system (T helper cells, lymphocytes and macro-
phages) and glial cells on the brain (see Fig. 2). Viral attach-
ment occurs via the gp120 envelope proteins (there is estimated 
to be 220 on each virion).8 Upon attachment gp120 interacts 
with another protein on the host cell surface, CD26 (not 
shown in Fig. 2). This interaction results in the exposure of a 
site on the gp41 viral envelope protein that fuses the viral enve-
lope with the host cell cytoplasmic membrane, resulting in the 
entry of the virus into the host cell.9 The viral coat is removed 
and the single-stranded RNA genome is reverse-transcribed to 
double-stranded cDNA by the enzyme reverse transcriptase.
This proviral DNA is transported into the host cell 
nucleus and integrated with the host genome at specific sites 
along the chromosome, by the viral enzyme integrase.10 This 
integrated viral genome is known as a provirus and is tran-
scribed and translated into new viral proteins.5 If the proviral 
DNA is activated it can produce new strands of RNA. This 
RNA either becomes messenger RNA, and is used for the 
production of viral proteins, or becomes encased within the 
viral core to become the new virus.6
The gag gene is transcribed and translated into a 
 polyprotein called p53, which is then cleaved into the core pro-
teins p7, p9, p17 and p24 by the HIV-coded protease. The pol 
gene is also transcribed, translated and proteolytically cleaved 
into reverse transcriptase, protease and intergrase polypep-
tides.11 The last gene to be transcribed and translated into the 
polyprotein gp160 is the env gene. Then, gp160 is cleaved into 
the envelope glycoproteins gp120 and gp41, which are incor-
porated into the host’s cytoplasmic membrane. The viral par-
ticles are then assembled and released slowly from the infected 
host cell by a process known as ‘budding’ (see Fig. 2).12
HIV Microbicides
HIV microbicides are formulations of chemical or biological 
agents that can be applied to the vagina or rectum with the 
intention of reducing the likelihood of acquisition of HIV. An 
effective microbicide product has the potential to reduce the 
global HIV infection rate.13–15 The ideal vaginal HIV microbi-
cide must have activity against cell-free and cell-associated HIV. 
It must not cause damage to the tissue or flora of the vagina. It 
must be retained in the vagina, act locally and retain its activity 
in the presence of semen and across a broad pH range.16
There are various mechanisms by which vaginal HIV 
microbicides may prevent HIV infection (see Fig.  3): 1) by 
destroying the virus as soon as it enters the vagina,17,18 2) main-
tenance of the vaginal flora, which provides a protective vaginal 
pH,19,20 3) prevention of HIV binding to CD4  receptors,21,22 
4) by preventing the HIV replication  process,23,24 5) by pro-
viding a physical barrier that prevents HIV from entering the 
vaginal mucosa,25 and 6) by prevention of sexually transmitted 
infection (STIs), which may increase the possibility of HIV 
infection.26
Reverse transcriptase inhibiting HIV microbicides. 
Reverse transcriptase inhibitors (RTIs), which inhibit the viral 
encoded enzyme reverse transcriptase responsible for the con-
version of single strand viral RNA into double-stranded DNA, 
are being evaluated as HIV microbicides. Both nucleotide and 
non-nucleoside reverse transcriptase inhibitors (NRTIs and 
NNRTIs) are under evaluation. NRTIs inhibit the process of 
reverse transcriptase by insertion into the propagating viral 
DNA, thereby inhibiting further synthesis of DNA. NNRTIs 
inhibit reverse transcriptase by binding directly to the reverse 
transcriptase enzyme and inhibiting the conversion of viral 
RNA into viral DNA.23,24
Tenofovir. Tenofovir (PMPA) is an NRTI that is phos-
phorylated by adenylate kinase to tenofovir diphosphate, 
which in turn competes with deoxyadeosine 5'-triphosphate 
for incorporation into newly synthesized DNA. Once incorpo-
rated, tenofovir diphosphate results in chain termination, thus 
inhibiting viral replication. Tenofovir is currently used in anti-
retroviral therapy for the treatment of HIV and is  marketed 
under the brand name Truvada®, which is a once daily tab-
let containing 300  mg of tenofovir and 200  mg of emtric-
itabine. Truvada® has been approved by the Food and Drug 
Efficacy of tenofovir in reducing the risk of HIV-1 and HSV-2 infection
3CliniCal MediCine insights: WoMen’s health 2014:7
Figure 2. hiV replication cycle.
Figure 3. Potential mechanisms of hiV prevention by a microbicide formulation: (1) provision of a physical barrier that prevents hiV from entering the 
vaginal mucosa,25 (2) maintenance of the vaginal flora, which provides a protective vaginal pH,19,20 (3) prevention of sexually transmitted infections (sti’s) 
which may increase the possibility of hiV infection,26 (4) by destroying the virus as soon as it enters the vagina,17,18 (5) prevention of hiV binding to Cd4 
receptors,21,22 (6) preventing the hiV replication process23,24 ultimately leading to the prevention of hiV uptake by the immune cells (7) (www.empro.org.uk).
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 combinations tenofovir-emtricitabine vs. abacavir- lamivudine, 
finding that both combinations had similar virological efficacy 
but abacavir-lamivudine was associated with more serious 
non-AIDS events, such as cardiovascular events.39
A phase  3 trial measured the efficacy of tenofovir- 
emtricitabine in HIV-1 infected, treatment-naive adults 
in combinational therapy with either efavirenz or a newer 
NNRTI, rilpivirine.40 The study showed that the  combination 
with rilpivirine had non-inferior efficacy compared to the 
combination with efavirenz, with higher virological failure 
but a more favourable safety and tolerability profile. A sin-
gle dose tablet combining the integrase inhibitor elvitegravir 
co- formulated with cobicistat, emtricitabine and tenofovir 
has been trialled,41 showing non-inferiority compared to the 
widely used combination efavirenz-emtricitabine-tenofovir. 
The new tablet offers the potential for a complete regimen 
in a single daily dose for initial treatment of HIV-1 infected 
patients. In protection against mother-to-child transmission, 
tenofovir-emtricitabine was trialled in combination with intra-
partum and neonatal single-dose nevirapine and was shown 
to reduce viral resistance to NNRTIs at 2 and 6 weeks after 
ingestion.42 A pharmacokinetic study involving oral tenofovir 
in combination with atazanavir-ritonavir in heavily pre-treated 
HIV  infected patients suggested the existence of significant 
interaction between atazanavir-ritonavir and tenofovir.43
The use of these same tenofovir-based oral dosage forms 
is now being examined in a number of trials to measure the 
effectiveness of such combinations as a prevention strategy in 
HIV-uninfected persons to reduce the transmission of HIV. 
The results from these trials have been complex and contrast-
ing. The FEM-PrEP (pre-exposure prophylaxis) trial studying 
African women was discontinued early because of a lack of 
protection.44 Contrastingly, the TDF2 study found an efficacy 
rate of about 62% for HIV prevention in both African men and 
women.45 The Partners PrEP study examined the use of daily 
oral tenofovir or tenofovir-emtricitabine in high-risk popu-
lations of sexually active women, men and HIV- discordant 
couples with an efficacy rate of approximately 75%.46
A phase 1 clinical trial of 0.3% and 1% tenofovir vagi-
nal gels in sexually active and sexually inactive HIV-negative 
and HIV-positive women found the gels to be safe, acceptable 
and well tolerated for a two-week twice daily course.47 A PK 
cross-over study comparing tenofovir vaginal gel and oral 
tablets found that gel dosing achieved lower serum concen-
trations but much higher vaginal tissue concentrations.48 The 
work suggested that topical gel should theoretically provide 
greater PrEP efficacy but noted that other factors had greater 
influence above the antiviral effect of tenofovir.
The Centre for the AIDS Program of Research in South 
Africa (CAPRISA) 004 trial assessed the effectiveness and 
safety of a 1% vaginal gel formulation of tenofovir for the 
 prevention of HIV acquisition in women.33 A double-blind, 
randomized controlled trial was conducted comparing teno-
fovir gel (n = 445 women) with placebo gel (n = 444 women) 
 Administration (FDA) for use as a pre-exposure prophylaxis 
strategy against HIV infection. Tenofovir is also marked as 
Atripla® (or Viraday®), which is a once daily combination tab-
let containing emtricitabine, tenofovir and efavirenz designed 
to increase compliance of antiretroviral therapy by reducing 
the pill-burden of HIV-positive patients. It has been demon-
strated that there is less chance of HIV developing resistance to 
tenofovir compared to other reverse transcriptase inhibitors.24 
Tenofovir’s efficacy, long half-life and safety profile make it an 
ideal candidate for use as an HIV microbicide strategy,27 while 
a study performed in SIV-positive macaques concluded that 
when they were treated systemically with either 30 mg/Kg or 
75 mg/Kg of PMPA the viral load was significantly reduced. 
However, the viral load increased when the treatment was 
stopped.28 Tenofovir’s potential for use as an HIV microbi-
cide was further corroborated by successful invitro and invivo 
assessment of a 1% tenofovir gel,27 while two macaque stud-
ies of tenofovir gels administered vaginally showed 100% and 
80% protection.29 Tenofovir’s efficacy against viral challenge 
in animal models has been established using either pre- or 
post-exposure prophylaxis administration.30–32
Tenofovir has also been shown to be effective against the 
herpes simplex virus-2 (HSV-2), with studies demonstrating 
that a tenofovir vaginal gel not only reduces HIV infection but 
surprisingly also suppresses HSV-2 infection.33 However, it has 
been demonstrated that administering tenofovir orally has no 
impact on HSV-2 infection.34 Andrei et al demonstrated that 
tenofovir inhibits the replication of HSV in a range of human 
clinical isolates and decreases HSV replication in human lym-
phoid and cervicovaginal tissues ex vivo, while delaying HSV-
induced lesions and death in topically treated HSV-infected 
mice. They concluded that tenofovir inhibits HSV-2 DNA-
polymerase, but in order to achieve effective drug concentra-
tions it must be administered topically rather than orally.35
Clinical Studies and Efficacy
Tenofovir has been comprehensively studied for safety, accept-
ability and efficacy. Primarily these studies have focused on 
the drug in an oral dosage form as part of antiretroviral (ARV) 
therapy and typically in combination with other antiretrovi-
rals. A three-year trial evaluating the safety and efficacy of 
tenofovir vs. stavudine when taken in combination with lami-
vudine and efavirenz showed both compounds to be highly 
effective in ARV-naive patients, though tenofovir was associ-
ated with less toxicity than stavudine.36 A study examining 
a three-drug regimen of tenofovir, abacavir and lamivudine 
in HIV-infected, ARV-naive subjects showed an unacceptably 
high virologic non-response, leading to the authors’ conclu-
sion that combination therapies should not be given based 
on presumed efficacy of the individual drugs.37 In the CAS-
TLE study, fixed dose tenofovir-emtricitabine was shown to 
be effective in combination with either atazanavir-ritonavir 
once daily or lopinavir-ritonavir twice daily.38 The STEAL 
study compared safety and efficacy of once-daily, fixed dose 
Efficacy of tenofovir in reducing the risk of HIV-1 and HSV-2 infection
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 tenofovir-emtricitabine therapy leads to a reduction in spine 
and hip bone mineral density within the first 48  weeks.54 
Compared to other antiretrovirals the tenofovir-emtricitabine 
based therapy provided for a significant reduction in spine 
and hip bone mineral density. Study 903 found no significant 
nephrotoxicity or renal impairment, which had been reported 
previously among tenofovir-treated HIV patients.55–58 An 
additional 336-week open-label extension phase of Study 903 
for 86 patients reported no renal impairment.59 A review by 
Cooper et al that assessed the findings of 17 clinical trials 
of tenofovir therapies, including Study 903, concluded that 
although the use of the drug was associated with a statisti-
cally significant loss of renal function, the clinical magnitude 
of this effect was modest.60 The authors did not feel that the 
use of tenofovir needed to be restricted provided there was 
regular monitoring of renal function.
During the HPTN 050 trial of a tenofovir gel, at 
least one adverse event was reported by 92% of participat-
ing women; 70% of the reports involved ‘reproductive sys-
tem and breast disorders’ (according to MedDRA coding), 
predominantly involving the genital tract.47 Just under a 
third of the women (32%) using the gel experienced diar-
rhoea and general gastrointestinal symptoms. There was no 
specific adverse event pattern in relation to gel concentration 
or frequency of use. One severe adverse event occurred, a 
case of pelvic inflammatory disease that was possibly prod-
uct related and was successfully treated with antibiotics. One 
moderate adverse event, shallow vulvar ulcerations, resulted 
in the termination of further use of the gel for that partici-
pant. The most common adverse events were genital pruritus 
(23%), applicator site bruising (17%), applicator site erythema 
(17%) and vaginal discharge (15%). There was no difference 
in the levels of bone fracture among participants assigned to 
receive tenofovir gel and the placebo gel. In CAPRISA-004, 
use of 1% tenofovir vaginal gel was well-tolerated.33 While 
94% of women reported at least one adverse event, there were 
no product-related increases in renal impairment or genital 
adverse events. Cases of diarrhea were reported by 17% of 
women, but these tended to be mild, rarely requiring medi-
cation. The vaginal gel arm of the MTN 001 trial had very 
limited adverse events, particularly in comparison to the oral 
and combination arms.48 Transient and mild symptoms were 
expressed as nausea (3%) and headache (2%).
Patient Preference and Place in THerapy
The efficacy of 1% tenofovir gel is fundamentally linked to 
adherence, and the statistics would suggest that women are 
unwilling or unable to consistently use the gel as an integral 
part of their sex life. During the CAPRISA 004 trial, consis-
tent (80%) use of the gel both before and after intercourse 
provided a 54% decrease in the risk of HIV infection.33 The 
gel was half (28%) as effective against HIV infection if use of 
the gel was inconsistent (50%) with intercourse.  Adherence 
promotion in the form of  intensive monthly counselling and 
in sexually active, HIV-uninfected 18- to 40-year-old women 
in urban and rural KwaZulu-Natal, South Africa. The dosing 
strategy was based on the woman inserting a dose of gel within 
12 hours before sex and a second gel dose as soon as possible 
and within 12  hours after sex, with a maximum two doses 
within 24 hours. Overall tenofovir gel reduced HIV infection 
by approximately 39%, with the peak effectiveness observed 
after 12 months of the trial at 50% protection. Participants 
with high (80%), intermediate (50–80%) and low (50%) 
gel adherence showed varying degrees of protection of 54%, 
38% and 28% respectively. Whilst the sample size and number 
of sites was relatively small in this study, it provided promising 
evidence that coitally related dosing of tenofovir appears safe 
and effective in preventing HIV infection in women.
VOICE—Vaginal and Oral Interventions to Control 
the Epidemic was a major HIV prevention trial evaluating 
safety and efficacy of 3 ARV products: an oral tablet contain-
ing tenofovir, an oral tablet containing both tenofovir and 
emtricitabine and a tenofovir gel for vaginal administration. 
Despite promising results from the Partner PrEP trial, which 
examined both tenofovir only and tenofovir plus emtricitabine 
oral tablets taken once daily, the once-daily oral tenofovir 
only arm of VOICE was stopped early due to futility.49 The 
same occurred with the vaginal gel arm, which examined 
the daily administration of a 1% tenofovir gel,50 despite the 
CAPRISA-004 trial showing an efficacy of around 39%, 
where the gel was administered 12 hours before sex and a sec-
ond dose as soon as possible (and within 12 hours) after sex. 
The result highlighted the importance of dosing regimens for 
the vaginal gel product.
Safety
Deeks assessed the short-term safety of tenofovir in 20 HIV-
infected adults administered by intravenous infusion.51 In 
this phase  1/2 clinical study, tenofovir appeared to be safe 
and well tolerated, with the most frequently reported adverse 
events mild and transient (grade I) such as headache, dizzi-
ness, fatigue and nausea. Three moderate (grade II) adverse 
events were also reported of nausea, fatigue and abdominal 
pain, all of which resolved without discontinuation of the 
drug. Tenofovir formulated as a once-a-day 300  mg single 
tablet has been extensively studied for efficacy and safety 
for the treatment of HIV-1 infections.52 A 24-week inves-
tigation by Gilead into the safety of this tenofovir therapy 
showed a similar toxicity profile to that of placebo.53 A larger 
600-patient Gilead Sciences Study GS-99-903 (Study 903) 
compared a combination treatment of tenofovir, lamivudine 
and efavirenz with a combination treatment of stavudine, 
lamivudine and efavirenzin antiretroviral-naïve patients in 
a randomized, double-blind, parallel, placebo-controlled 
trial over 144  weeks.36 During Study 903, a decrease in 
bone mineral density at the spine and hip was seen in the 
first 48  weeks but was non-progressive over the remaining 
weeks. The A5224s trial has also recently reported that a 
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diaphragms,68,69 and tablets,70 which can offer women many 
different choices to meet their individual needs.
Conclusion
As no HIV vaccine will likely be available in the near future, 
there needs to be a push towards the development of HIV 
microbicide products that will reduce the rate of new HIV 
infections. The encouraging data from the CAPRISA 004 
clinical trial may do just that. However, there is an overreli-
ance on reverse transcriptase inhibitors (RTI), like tenofovir, 
for use as HIV microbicides and there needs to be a move 
towards developing and clinically testing other potential can-
didates, such as entry inhibitors, integrase inhibitors and pro-
tease inhibitors, as well as various peptide- and protein-based 
molecules. Furthermore, the microbicide field needs to develop 
and clinically test a range of vaginal dosage forms, including 
gels, tablets, rings and films, because no one product is going to 
alleviate the adherence issues associated with the 1% tenofovir 
gel tested in the CAPRISA 004 study. A range of products 
needs to be made available to women, allowing them to choose 
the product(s) that best suits their (and their partners’) sexual 
needs. Therefore, the 1% tenofovir gel will not be the single 
HIV microbicide product available, but will be part of a much 
wider range of products, which consists of a number of different 
dosage forms containing a range of different active ingredients, 
allowing for a dosing regimen tailored towards the individual.
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motivational interviewing of participants only provided for 
overall adherence of 38% of women using the gel 80% before 
and after intercourse. The microbicide community still need to 
address this problem of low adherence for vaginal gels. They 
must clearly understand what prevents gels from being an 
integral part of the sex life of at-risk women; otherwise such 
products will have only a limited place in prophylaxis.
Is a lack of acceptability for the gel, particularly among 
at-risk women, the root cause of this low adherence? Women 
have shown a clear preference for and have a high acceptance 
for vaginal gels. An early study among Brazilian women 
examined their preferences for vaginal antimicrobial contra-
ceptives; there was clear preference for a gel (39.6%) compared 
to other dosage forms, such as creams and films.61 During the 
HPTN 050 trial,62 94% of participating women were fully 
adherent and said they definitely or probably would use the 
product if they were worried about being infected by or trans-
mitting HIV, indicating that the gel was highly acceptable. 
Overall, the gel was liked by 79% of the women and 76% of 
male partners. However, a significant portion of these same 
women did report issues with the product that are already 
well-known disadvantages of vaginal gels. Leakage—before 
(41%), during (50%) and after (68%) sex—was the most com-
mon issue reported by the women. Non-intercourse-related 
leakage was also commonly reported. Several women found 
the gel messy to an unacceptable level. Some found the leak-
age significant, leaving them feeling moist and uncomfortable 
for considerable periods of time, compelling a more rigorous 
hygiene regime to compensate. Two thirds of women experi-
enced leakage or messiness, while the remainder did not find 
the gel messy and did not experience significant leakage. Of 
sexually-active participants, 86% felt the gel provided for wet-
ter sex, with a mixed reaction to whether or not this increased, 
decreased or made no difference to sexual pleasure. 90% of 
the women indicated either that the gel increased their sexual 
pleasure or that it made no difference.
The acceptability of the vaginal gel approach is clearly 
dependent on the effect the product has on the personal 
hygiene of the woman and on sexual intimacy with her partner. 
A recent review of vaginal HIV microbicides highlights clearly 
the importance and complexity the issue of wetness has in the 
acceptance of gel products in terms of personal hygiene, female 
preference, male preference and a women’s perception of her 
partner’s preference.63 This review highlights the sometimes 
contradictory findings into the preferences for gel attributes 
among women and men, as well as the type of sex (dry or wet) 
preferred and how this influences the choices women make in 
continuing to use certain vaginal products. Adherence is the 
single most important factor controlling the effectiveness of 
potent microbicide gels and adherence appears tied up in the 
complex issue of acceptability. The 1% tenofovir gel, and other 
microbicidal gels that may follow, will find a place in therapy 
not as a single therapy in the field of vaginal microbicides but 
one of a number of therapies, including rings,64,65 films,66,67 
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